Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinic
17 Luglio 2007 - 3:23PM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) today announced the publication
of preclinical data demonstrating that its Toll-like Receptor (TLR)
9 agonist in combination with bevacizumab, the anti-vascular
endothelial growth factor (VEGF) monoclonal antibody, resulted in
co-operative anti-tumor activity in animal models of colon cancer.
Bevacizumab is marketed as Avastin�. The paper entitled �Novel TLR9
agonist synergizes by different mechanisms with bevacizumab in
sensitive and cetuximab-resistant colon cancer xenografts� is
published in the Proceedings of National Academy of Sciences (Vol.
104: 12468-12473, 2007). The authors of the paper include Vincenzo
Damiano, Rosa Caputo, Sonia Garofalo, Roberto Bianco, Roberta Rosa,
Luigi Racioppi, Gerardina Merola, Sabino De Placido, Fortunato
Ciardiello, Gabriella Fontanini and Giampaolo Tortora of the
University of Naples Federico II and University of Pisa, Italy; and
Ekambar Kandimalla and Sudhir Agrawal of Idera. �Combination
therapy utilizing a variety of anti-tumor mechanisms has become a
highly successful therapeutic strategy for a number of cancer
indications. The results described in the paper suggest that the
TLR9 agonist, in addition to being an immune modifier, also affects
the epidermal growth factor receptor (EGFR) and VEGF pathways,�
commented Sudhir Agrawal D. Phil., Chief Executive Officer and
Chief Scientific Officer. �These findings support our intention to
expand our oncology clinical development strategy with IMO-2055, a
TLR9 agonist, in combination therapy regimens with targeted agents
including Tarceva�, Avastin and Erbitux�.� About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company that is developing drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases, and
for use as vaccine adjuvants. Idera�s proprietary drug candidates
are designed to modulate TLRs, the body�s first line of immune
defense. Idera�s pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera�s most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera is collaborating with Novartis
International Pharmaceutical, Ltd. for the discovery, development,
and commercialization of TLR9 agonists for the treatment of asthma
and allergy indications. Idera is also collaborating with Merck
& Co., Inc. for the use of Idera�s TLR7, 8 and 9 agonists in
combination with Merck�s therapeutic and prophylactic vaccines in
the areas of oncology, infectious diseases, and Alzheimer�s
disease. For more information, visit www.iderapharma.com. Forward
Looking Statements This press release contains forward-looking
statements concerning Idera Pharmaceuticals, Inc. that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Idera�s actual results to differ materially from those
indicated by such forward-looking statements, including whether
products based on Idera�s technology will advance into or through
the clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company�s
products receive approval, they will be successfully distributed
and marketed; whether the Company�s collaborations with Novartis
and Merck will be successful; whether Idera�s cash resources will
be sufficient to fund product development and clinical trials; and
such other important factors as are set forth under the caption
"Risk Factors" in Idera�s Quarterly Report on Form 10-Q filed on
May 14, 2007, which important factors are incorporated herein by
reference. Idera disclaims any intention or obligation to update
any forward-looking statements. Avastin is a registered trademark
of Genentech, Inc. Tarceva is a registered trademark of OSI
Pharmaceuticals, Inc. Erbitux is a registered trademark of ImClone
Systems Incorporated.
Grafico Azioni Idera Pharmaceutical (AMEX:IDP)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Idera Pharmaceutical (AMEX:IDP)
Storico
Da Set 2023 a Set 2024